ArticleBMC bioinformatics2025
Contrastive learning-based multi-mechanism disentangled assessment for drug-drug interaction.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPolypharmacy's ability to circumvent acquired resistance to single drug makes it a critical strategy for treating complex diseases. However, it inevitably carries risks of drug-drug interactions (DDIs) that may alter pharmacological activities and potentially lead to severe adverse events or mortality. Computational assessment of drug combination has emerged as an effective approach to support clinical decision-making. Current risk identification methods focus on mining historical interaction patterns to uncover underlying mechanisms, yet face challenges from data sparsity. While data augmentation strategy can mitigate such problem, conventional approaches often introduce noise that obscures core pharmacological mechanisms, undermining safety evaluation.
resultsThis study proposes a Multi-Mechanism Disentangled Drug-drug Interaction assessment framework integrated contrastive learning, MMDDI, which includes two key components: (1) biologically-informed multi-view generation that creates high-quality augmented views, effectively addressing semantic distortion during data augmentation; (2) Mechanism-aware disentanglement that incorporates mutual information constraints to isolate interaction mechanisms from coupling of multi-modal and heterogeneous data, eliminating quantification bias. Contrastive learning integrates labeled and unlabeled data to enhance robustness against sparse observations.
conclusionsComprehensive evaluations demonstrate that MMDDI with hit@4 of 0.86 outperforms the compared baselines, with ablation studies validating the critical contributions of multi-view contrastive and mechanism disentanglement. MMDDI continues to demonstrate excellent performance in cold-start scenarios, achieving accuracy of 0.94 and recall of 0.95. Clinically, MMDDI enables interpretable causal analysis of drug interaction pathways through its mechanism-aware representations, providing operability for optimizing therapeutic regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.